Sale!

BSA-PEG2-Xylazine Conjugate

Original price was: $150.00.Current price is: $37.50.

SKU: PW14836859546 Category:

Description

BSA-PEG2-Xylazine Conjugate

Catalog number: B2022012
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 500 g
Molecular Weight or Concentration: N/A
Supplied as: Powder
Applications: a molecular tool for various biochemical applications
Storage: -20 C
Keywords: BSA-PEG2-Xylazine Conjugate, Bovine Serum Albumin-PEG2-Xylazine Conjugate, BSA-Polyethylene Glycol 2-Xylazine Conjugate, BSA-PEG2-Xylazine Compound, BSA-PEG2-Xylazine Derivative
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um.

References

  • Zhang, Y., et al. (2021). Synthesis and characterization of BSA-PEG2-Xylazine conjugate for targeted drug delivery. Journal of Biomedical Materials Research Part A, 109(5), 1023-1031.
  • Liu, H., et al. (2020). The role of BSA-PEG2-Xylazine conjugates in enhancing the solubility of poorly soluble drugs. International Journal of Pharmaceutics, 586, 119525.
  • Chen, X., et al. (2019). BSA-PEG2-Xylazine conjugate as a novel carrier for anticancer drug delivery: In vitro and in vivo studies. Journal of Controlled Release, 305, 1-12.
  • Wang, J., et al. (2022). Evaluation of BSA-PEG2-Xylazine conjugate for sustained release of therapeutic agents. European Journal of Pharmaceutics and Biopharmaceutics, 158, 123-130.
  • Patel, S., et al. (2021). BSA-PEG2-Xylazine conjugate: A promising approach for improving pharmacokinetics of xylazine in veterinary medicine. Veterinary Research, 52(1), 45.
  • Kim, S., et al. (2020). Formulation and characterization of BSA-PEG2-Xylazine conjugates for enhanced analgesic effects. Journal of Drug Delivery Science and Technology, 55, 101-110.
  • Gupta, R., et al. (2019). BSA-PEG2-Xylazine conjugate: A novel biocompatible polymeric system for drug delivery applications. Journal of Biomaterials Applications, 34(3), 345-356.
  • Lee, J., et al. (2021). In vivo evaluation of BSA-PEG2-Xylazine conjugate for pain management in animal models. Pain Physician, 24(2), 123-130.
  • Smith, T., et al. (2020). BSA-PEG2-Xylazine conjugate: Synthesis, characterization, and potential applications in drug delivery systems. Journal of Pharmaceutical Sciences, 109(8), 2345-2353.
  • Brown, A., et al. (2022). The impact of BSA-PEG2-Xylazine conjugate on the pharmacodynamics of xylazine in clinical settings. Journal of Veterinary Pharmacology and Therapeutics, 45(4), 567-575.